Section Arrow
DCTH.NASDAQ
- Delcath Systems
Quotes are at least 15-min delayed:2025/04/30 00:09 EDT
Last
 12.2
+0.2 (+1.67%)
Day High 
12.3675 
Prev. Close
12 
1-M High
13.39 
Volume 
268.59K 
Bid
11.82
Ask
14.01
Day Low
11.82 
Open
11.94 
1-M Low
9.78 
Market Cap 
401.19M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.75 
20-SMA 11.64 
50-SMA 12.92 
52-W High 16.97 
52-W Low 5.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.93/0.54
Enterprise Value
402.12M
Balance Sheet
Book Value Per Share
2.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
37.21M
Operating Revenue Per Share
0.08
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BSXBoston Scientific Corp102.74+0.56+0.55%82.3PE
PACBPacific Biosciences of California1.11-0.02-1.77%-- 
MDTMedtronic plc84.6+0.56+0.67%25.62PE
EWEdwards Lifesciences Corp76.28+0.74+0.98%32.28PE
ABTAbbott Laboratories130.5+0.97+0.75%16.95PE
Quotes are at least 15-min delayed:2025/04/30 00:09 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS,is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.